Wegovy Oral GLP-1 Approved; First Obesity Oral Medication

The FDA approved Novo Nordisk's Wegovy oral GLP-1 for obesity indication, marking the first oral GLP-1 for weight loss. Full U.S. market entry began in January, signaling a price decline and oral medication expansion cycle in 2026.